User login
Smoldering multiple myeloma affects 1 in 7 patients
About 1 in 7 cases of multiple myeloma diagnosed in the United States are cases of smoldering disease, according to an analysis of data from the National Cancer Data Base, which represents 70% of cancer cases.
The prevalence of smoldering multiple myeloma varied among various socio- and geodemographic subgroups, but overall survival did not, Aishwarya Ravindran, MBBS, of Mayo Clinic, Rochester, Minn., and colleagues reported at the annual meeting of the American Society of Clinical Oncology. “Our results can be used in the future to study the health care impact of SMM,” the researchers wrote in a poster presentation.
Epidemiologic studies of smoldering multiple myeloma have been limited by the lack of International Classification of Diseases codes specific for smoldering status, the researchers said.
They analyzed 86,327 cases of multiple myeloma, considering socio- and geodemographic subgroups and type of treatment facility. Overall survival was compared for smoldering and active multiple myeloma. The researchers included patients enrolled in the database during 2003-2011; records were examined from the time to initial treatment and they considered reasons for patients not receiving treatment.
Patients who did not require treatment within the first 120 days after diagnosis were considered to have smoldering disease. This group comprised almost 14% of the cases.
The proportion of cases that were smoldering disease did not change significantly during the study period (P = .23 and .34, respectively). Smoldering disease was more likely to be diagnosed among women, black patients, older patients (median age at diagnosis was 67 years), and less educated patients. Smoldering disease was more common in patients with fewer medical comorbidities, those living closer to a treatment facility, and those evaluated for their disease in the Northeast United States. The proportions of cases diagnosed at academic and nonacademic facilities were similar.
The median overall survival for smoldering disease was 63 months; for active disease, 33 months. Overall survival in those with smoldering disease did not differ among the racial groups (P = .27).
The researchers had no financial conflicts.
On Twitter @maryjodales
About 1 in 7 cases of multiple myeloma diagnosed in the United States are cases of smoldering disease, according to an analysis of data from the National Cancer Data Base, which represents 70% of cancer cases.
The prevalence of smoldering multiple myeloma varied among various socio- and geodemographic subgroups, but overall survival did not, Aishwarya Ravindran, MBBS, of Mayo Clinic, Rochester, Minn., and colleagues reported at the annual meeting of the American Society of Clinical Oncology. “Our results can be used in the future to study the health care impact of SMM,” the researchers wrote in a poster presentation.
Epidemiologic studies of smoldering multiple myeloma have been limited by the lack of International Classification of Diseases codes specific for smoldering status, the researchers said.
They analyzed 86,327 cases of multiple myeloma, considering socio- and geodemographic subgroups and type of treatment facility. Overall survival was compared for smoldering and active multiple myeloma. The researchers included patients enrolled in the database during 2003-2011; records were examined from the time to initial treatment and they considered reasons for patients not receiving treatment.
Patients who did not require treatment within the first 120 days after diagnosis were considered to have smoldering disease. This group comprised almost 14% of the cases.
The proportion of cases that were smoldering disease did not change significantly during the study period (P = .23 and .34, respectively). Smoldering disease was more likely to be diagnosed among women, black patients, older patients (median age at diagnosis was 67 years), and less educated patients. Smoldering disease was more common in patients with fewer medical comorbidities, those living closer to a treatment facility, and those evaluated for their disease in the Northeast United States. The proportions of cases diagnosed at academic and nonacademic facilities were similar.
The median overall survival for smoldering disease was 63 months; for active disease, 33 months. Overall survival in those with smoldering disease did not differ among the racial groups (P = .27).
The researchers had no financial conflicts.
On Twitter @maryjodales
About 1 in 7 cases of multiple myeloma diagnosed in the United States are cases of smoldering disease, according to an analysis of data from the National Cancer Data Base, which represents 70% of cancer cases.
The prevalence of smoldering multiple myeloma varied among various socio- and geodemographic subgroups, but overall survival did not, Aishwarya Ravindran, MBBS, of Mayo Clinic, Rochester, Minn., and colleagues reported at the annual meeting of the American Society of Clinical Oncology. “Our results can be used in the future to study the health care impact of SMM,” the researchers wrote in a poster presentation.
Epidemiologic studies of smoldering multiple myeloma have been limited by the lack of International Classification of Diseases codes specific for smoldering status, the researchers said.
They analyzed 86,327 cases of multiple myeloma, considering socio- and geodemographic subgroups and type of treatment facility. Overall survival was compared for smoldering and active multiple myeloma. The researchers included patients enrolled in the database during 2003-2011; records were examined from the time to initial treatment and they considered reasons for patients not receiving treatment.
Patients who did not require treatment within the first 120 days after diagnosis were considered to have smoldering disease. This group comprised almost 14% of the cases.
The proportion of cases that were smoldering disease did not change significantly during the study period (P = .23 and .34, respectively). Smoldering disease was more likely to be diagnosed among women, black patients, older patients (median age at diagnosis was 67 years), and less educated patients. Smoldering disease was more common in patients with fewer medical comorbidities, those living closer to a treatment facility, and those evaluated for their disease in the Northeast United States. The proportions of cases diagnosed at academic and nonacademic facilities were similar.
The median overall survival for smoldering disease was 63 months; for active disease, 33 months. Overall survival in those with smoldering disease did not differ among the racial groups (P = .27).
The researchers had no financial conflicts.
On Twitter @maryjodales
FROM ASCO 2016
Key clinical point: The prevalence of smoldering multiple myeloma varied among various socio- and geodemographic subgroups, but overall survival did not.
Major finding: About 1 in 7 cases of multiple myeloma diagnosed in the United States are cases of smoldering disease.
Data source: At total of 86,327 cases of multiple myeloma from the National Cancer Data Base, which represents 70% of cancer cases.
Disclosures: The researchers had no financial conflicts.
2016 Annual Meeting Competition Winners
19th Annual C. Walton Lillehei Resident Forum
Through a generous unrestricted educational grant from St. Jude Medical, the Forum enables eight residents to present and compete for a $5,000 award.
Rachel D. Vanderlaan /University of Toronto
“Mechanistic Insights into the Pathophysiology of Pulmonary Vein Stenosis”
Moderated Poster Competition
Adult Cardiac
Sameh M. Said/Mayo Clinic
“Long-term Outcomes of Surgery for Infective Endocarditis: A Single-center Experience of 801 Patients”
Congenital
Sachin Talwar/All India Institute of Medical Sciences
“Oral Thyroxin Supplementation in Infants Undergoing Cardiac Surgery: A Double Blind Randomized Clinical Trial”
General Thoracic
Jules Lin/University of Michigan
“Analytic Morphomics Predict Outcomes After Lung Volume Reduction Surgery”
19th Annual C. Walton Lillehei Resident Forum
Through a generous unrestricted educational grant from St. Jude Medical, the Forum enables eight residents to present and compete for a $5,000 award.
Rachel D. Vanderlaan /University of Toronto
“Mechanistic Insights into the Pathophysiology of Pulmonary Vein Stenosis”
Moderated Poster Competition
Adult Cardiac
Sameh M. Said/Mayo Clinic
“Long-term Outcomes of Surgery for Infective Endocarditis: A Single-center Experience of 801 Patients”
Congenital
Sachin Talwar/All India Institute of Medical Sciences
“Oral Thyroxin Supplementation in Infants Undergoing Cardiac Surgery: A Double Blind Randomized Clinical Trial”
General Thoracic
Jules Lin/University of Michigan
“Analytic Morphomics Predict Outcomes After Lung Volume Reduction Surgery”
19th Annual C. Walton Lillehei Resident Forum
Through a generous unrestricted educational grant from St. Jude Medical, the Forum enables eight residents to present and compete for a $5,000 award.
Rachel D. Vanderlaan /University of Toronto
“Mechanistic Insights into the Pathophysiology of Pulmonary Vein Stenosis”
Moderated Poster Competition
Adult Cardiac
Sameh M. Said/Mayo Clinic
“Long-term Outcomes of Surgery for Infective Endocarditis: A Single-center Experience of 801 Patients”
Congenital
Sachin Talwar/All India Institute of Medical Sciences
“Oral Thyroxin Supplementation in Infants Undergoing Cardiac Surgery: A Double Blind Randomized Clinical Trial”
General Thoracic
Jules Lin/University of Michigan
“Analytic Morphomics Predict Outcomes After Lung Volume Reduction Surgery”
AATS Week 2016 Recap
AATS Week 2016 was a great success
Starting May 12 and 13 in New York City, more than 1,250 attendees took part in the AATS Aortic Symposium. The Friday Breakfast Sessions were particularly popular — Stump the Stars I: Open Surgery Cases, Stump the Stars II: Endovascular Cases, and Controversies in Aortic Surgery.
The week’s activities continued from May 14 - 18 at the AATS Annual Meeting in Baltimore. On hand were some 2,514 cardiothoracic surgeons and health care professionals, as well as residents, fellows, medical students and others in the field.
Program Highlights
Saturday Skills Courses:Combined Luncheon Speaker Denton A. Cooley, followed by hands-on sessions.
Sunday Postgraduate Symposia with Legends Luncheons featuring Leonard L. Bailey, Joel D. Cooper and John L. Ochsner.
New course: The Survival Guide for the Cardiothoracic Surgical Team aimed at residents, fellows and health care professionals, followed by a hands-on session.
Emerging Technologies & Techniques Fora: Adult Cardiac and General Thoracic
Surgical Ethics Course: Surgeons Solving Ethical Problems in Surgery — A day-long program focusing on ethical issues faced by surgeons, especially problems created by rapidly evolving technologies. Course chairs were Martin F. McKneally, University of Toronto and Robert M. Sade, Medical University of South Carolina.
VAD/ECMO Session
Masters of Surgery Video Sessions
AATS Learning Center — Located in the Exhibit Hall, the Center had nine stations of cutting-edge case videos of novel procedures and surgical techniques. Subject areas were: the “best” of the 2015 Mitral Conclave and 2016 Aortic Symposium, aortic surgery, congenital heart disease, esophagus and diaphragm, intracardiac masses, lung, mediastinum, and mitral valve surgery.
AATS Week 2016 was a great success
Starting May 12 and 13 in New York City, more than 1,250 attendees took part in the AATS Aortic Symposium. The Friday Breakfast Sessions were particularly popular — Stump the Stars I: Open Surgery Cases, Stump the Stars II: Endovascular Cases, and Controversies in Aortic Surgery.
The week’s activities continued from May 14 - 18 at the AATS Annual Meeting in Baltimore. On hand were some 2,514 cardiothoracic surgeons and health care professionals, as well as residents, fellows, medical students and others in the field.
Program Highlights
Saturday Skills Courses:Combined Luncheon Speaker Denton A. Cooley, followed by hands-on sessions.
Sunday Postgraduate Symposia with Legends Luncheons featuring Leonard L. Bailey, Joel D. Cooper and John L. Ochsner.
New course: The Survival Guide for the Cardiothoracic Surgical Team aimed at residents, fellows and health care professionals, followed by a hands-on session.
Emerging Technologies & Techniques Fora: Adult Cardiac and General Thoracic
Surgical Ethics Course: Surgeons Solving Ethical Problems in Surgery — A day-long program focusing on ethical issues faced by surgeons, especially problems created by rapidly evolving technologies. Course chairs were Martin F. McKneally, University of Toronto and Robert M. Sade, Medical University of South Carolina.
VAD/ECMO Session
Masters of Surgery Video Sessions
AATS Learning Center — Located in the Exhibit Hall, the Center had nine stations of cutting-edge case videos of novel procedures and surgical techniques. Subject areas were: the “best” of the 2015 Mitral Conclave and 2016 Aortic Symposium, aortic surgery, congenital heart disease, esophagus and diaphragm, intracardiac masses, lung, mediastinum, and mitral valve surgery.
AATS Week 2016 was a great success
Starting May 12 and 13 in New York City, more than 1,250 attendees took part in the AATS Aortic Symposium. The Friday Breakfast Sessions were particularly popular — Stump the Stars I: Open Surgery Cases, Stump the Stars II: Endovascular Cases, and Controversies in Aortic Surgery.
The week’s activities continued from May 14 - 18 at the AATS Annual Meeting in Baltimore. On hand were some 2,514 cardiothoracic surgeons and health care professionals, as well as residents, fellows, medical students and others in the field.
Program Highlights
Saturday Skills Courses:Combined Luncheon Speaker Denton A. Cooley, followed by hands-on sessions.
Sunday Postgraduate Symposia with Legends Luncheons featuring Leonard L. Bailey, Joel D. Cooper and John L. Ochsner.
New course: The Survival Guide for the Cardiothoracic Surgical Team aimed at residents, fellows and health care professionals, followed by a hands-on session.
Emerging Technologies & Techniques Fora: Adult Cardiac and General Thoracic
Surgical Ethics Course: Surgeons Solving Ethical Problems in Surgery — A day-long program focusing on ethical issues faced by surgeons, especially problems created by rapidly evolving technologies. Course chairs were Martin F. McKneally, University of Toronto and Robert M. Sade, Medical University of South Carolina.
VAD/ECMO Session
Masters of Surgery Video Sessions
AATS Learning Center — Located in the Exhibit Hall, the Center had nine stations of cutting-edge case videos of novel procedures and surgical techniques. Subject areas were: the “best” of the 2015 Mitral Conclave and 2016 Aortic Symposium, aortic surgery, congenital heart disease, esophagus and diaphragm, intracardiac masses, lung, mediastinum, and mitral valve surgery.
AATS Annual Meeting Speakers
Attendees in Baltimore had the opportunity to experience several terrific talks by top speakers:
Joseph S. Coselli, Baylor College of Medicine
Presidential Address
Competition: Perspiration to Inspiration “Aut viam inveniam aut faciam”
Gary H. Gibbons, National Heart, Blood & Lung Institute
Basic Science Lecture
Charting Our Future Together: Translating Discovery Science into Health Impact
Brian Kelly, Notre Dame Head Football Coach
Honored Guest Lecture
The Building Blocks for Success: Leadership — Program Building — Player Development
Attendees in Baltimore had the opportunity to experience several terrific talks by top speakers:
Joseph S. Coselli, Baylor College of Medicine
Presidential Address
Competition: Perspiration to Inspiration “Aut viam inveniam aut faciam”
Gary H. Gibbons, National Heart, Blood & Lung Institute
Basic Science Lecture
Charting Our Future Together: Translating Discovery Science into Health Impact
Brian Kelly, Notre Dame Head Football Coach
Honored Guest Lecture
The Building Blocks for Success: Leadership — Program Building — Player Development
Attendees in Baltimore had the opportunity to experience several terrific talks by top speakers:
Joseph S. Coselli, Baylor College of Medicine
Presidential Address
Competition: Perspiration to Inspiration “Aut viam inveniam aut faciam”
Gary H. Gibbons, National Heart, Blood & Lung Institute
Basic Science Lecture
Charting Our Future Together: Translating Discovery Science into Health Impact
Brian Kelly, Notre Dame Head Football Coach
Honored Guest Lecture
The Building Blocks for Success: Leadership — Program Building — Player Development
2016 AATS Lifetime Achievement Award Honors Denton A. Cooley
Denton A. Cooley of the Texas Heart Institute was honored with the 2016 AATS Lifetime Achievement Award during the Annual Meeting Plenary Session on Monday, May 16th.
The award was accepted by his daughter (above right) from Dr. Joseph Coselli.
The award recognizes individuals for their significant contributions to CT surgery patient care, teaching, research or community service.
The honor acknowledges Cooley’s dedication, service and pioneering efforts, including the first successful human heart transplant in the United States and first artificial heart implant.
Denton A. Cooley of the Texas Heart Institute was honored with the 2016 AATS Lifetime Achievement Award during the Annual Meeting Plenary Session on Monday, May 16th.
The award was accepted by his daughter (above right) from Dr. Joseph Coselli.
The award recognizes individuals for their significant contributions to CT surgery patient care, teaching, research or community service.
The honor acknowledges Cooley’s dedication, service and pioneering efforts, including the first successful human heart transplant in the United States and first artificial heart implant.
Denton A. Cooley of the Texas Heart Institute was honored with the 2016 AATS Lifetime Achievement Award during the Annual Meeting Plenary Session on Monday, May 16th.
The award was accepted by his daughter (above right) from Dr. Joseph Coselli.
The award recognizes individuals for their significant contributions to CT surgery patient care, teaching, research or community service.
The honor acknowledges Cooley’s dedication, service and pioneering efforts, including the first successful human heart transplant in the United States and first artificial heart implant.
Case Study: Managing Opioid Addiction After a Back Injury
Has your patient’s opioid use escalated to opioid addiction? How can you tell, and what interventions can you take to help this patient in the context of a 15-minute appointment?
In this edition of Mental Health Consult, our panel discusses their recommendations for workup and next steps for managing a 45-year-old man who has no history of psychiatric disorders and appears to now be dependent on the opioid painkillers that he initially received after a back injury.
Join our panel of experts from George Washington University, Washington, including Daniel Lieberman, MD, professor of psychiatry and behavioral sciences clinical director; April Barbour, MD, MPH, director of the division of general internal medicine; and Lorenzo Norris, MD, medical director of psychiatric and behavioral services, as they discuss how to treat pain medication–related addiction, including when to refer to pain specialists and how various practice models drive treatment decisions and reimbursement.
Click here for a PDF of the case study.
Has your patient’s opioid use escalated to opioid addiction? How can you tell, and what interventions can you take to help this patient in the context of a 15-minute appointment?
In this edition of Mental Health Consult, our panel discusses their recommendations for workup and next steps for managing a 45-year-old man who has no history of psychiatric disorders and appears to now be dependent on the opioid painkillers that he initially received after a back injury.
Join our panel of experts from George Washington University, Washington, including Daniel Lieberman, MD, professor of psychiatry and behavioral sciences clinical director; April Barbour, MD, MPH, director of the division of general internal medicine; and Lorenzo Norris, MD, medical director of psychiatric and behavioral services, as they discuss how to treat pain medication–related addiction, including when to refer to pain specialists and how various practice models drive treatment decisions and reimbursement.
Click here for a PDF of the case study.
Has your patient’s opioid use escalated to opioid addiction? How can you tell, and what interventions can you take to help this patient in the context of a 15-minute appointment?
In this edition of Mental Health Consult, our panel discusses their recommendations for workup and next steps for managing a 45-year-old man who has no history of psychiatric disorders and appears to now be dependent on the opioid painkillers that he initially received after a back injury.
Join our panel of experts from George Washington University, Washington, including Daniel Lieberman, MD, professor of psychiatry and behavioral sciences clinical director; April Barbour, MD, MPH, director of the division of general internal medicine; and Lorenzo Norris, MD, medical director of psychiatric and behavioral services, as they discuss how to treat pain medication–related addiction, including when to refer to pain specialists and how various practice models drive treatment decisions and reimbursement.
Click here for a PDF of the case study.
VIDEO: A case study in managing opioid addiction after a back injury
Has your patient’s opioid use escalated to opioid addiction? How can you tell, and what interventions can you take to help this patient in the context of a 15-minute appointment?
In this edition of Mental Health Consult, our panel discusses their recommendations for workup and next steps for managing a 45-year-old man who has no history of psychiatric disorders and appears to now be dependent on the opioid painkillers that he initially received after a back injury.
Join our panel of experts from George Washington University, Washington, including Daniel Lieberman, MD, professor of psychiatry and behavioral sciences clinical director; April Barbour, MD, MPH, director of the division of general internal medicine; and Lorenzo Norris, MD, medical director of psychiatric and behavioral services, as they discuss how to treat pain medication–related addiction, including when to refer to pain specialists and how various practice models drive treatment decisions and reimbursement.
On Twitter @whitneymcknight
Has your patient’s opioid use escalated to opioid addiction? How can you tell, and what interventions can you take to help this patient in the context of a 15-minute appointment?
In this edition of Mental Health Consult, our panel discusses their recommendations for workup and next steps for managing a 45-year-old man who has no history of psychiatric disorders and appears to now be dependent on the opioid painkillers that he initially received after a back injury.
Join our panel of experts from George Washington University, Washington, including Daniel Lieberman, MD, professor of psychiatry and behavioral sciences clinical director; April Barbour, MD, MPH, director of the division of general internal medicine; and Lorenzo Norris, MD, medical director of psychiatric and behavioral services, as they discuss how to treat pain medication–related addiction, including when to refer to pain specialists and how various practice models drive treatment decisions and reimbursement.
On Twitter @whitneymcknight
Has your patient’s opioid use escalated to opioid addiction? How can you tell, and what interventions can you take to help this patient in the context of a 15-minute appointment?
In this edition of Mental Health Consult, our panel discusses their recommendations for workup and next steps for managing a 45-year-old man who has no history of psychiatric disorders and appears to now be dependent on the opioid painkillers that he initially received after a back injury.
Join our panel of experts from George Washington University, Washington, including Daniel Lieberman, MD, professor of psychiatry and behavioral sciences clinical director; April Barbour, MD, MPH, director of the division of general internal medicine; and Lorenzo Norris, MD, medical director of psychiatric and behavioral services, as they discuss how to treat pain medication–related addiction, including when to refer to pain specialists and how various practice models drive treatment decisions and reimbursement.
On Twitter @whitneymcknight
2016 AATS Scientific Achievement Award Honors Tirone E. David
Tirone E. David of the University of Toronto was presented with the 2016 AATS Scientific Achievement Award during the Annual Meeting Plenary Session on May 16th.
Dr. David (above left) with his award is shown with Dr. Irving Kron.
The award is the Association’s highest scientific recognition. Created in 1994, it recognizes physicians who have made extraordinary scientific contributions to the CT surgery field.
The honor acknowledges David’s pioneering work in CT surgery and his service as 85th AATS President (2004-2005). During an illustrious career, his innovation, passion and dedication to CT surgery has impacted hundreds of trainees and peers. The David operation revolutionized the treatment of aortic valve disease and resulted in substantial advances in patient care quality worldwide.
Tirone E. David of the University of Toronto was presented with the 2016 AATS Scientific Achievement Award during the Annual Meeting Plenary Session on May 16th.
Dr. David (above left) with his award is shown with Dr. Irving Kron.
The award is the Association’s highest scientific recognition. Created in 1994, it recognizes physicians who have made extraordinary scientific contributions to the CT surgery field.
The honor acknowledges David’s pioneering work in CT surgery and his service as 85th AATS President (2004-2005). During an illustrious career, his innovation, passion and dedication to CT surgery has impacted hundreds of trainees and peers. The David operation revolutionized the treatment of aortic valve disease and resulted in substantial advances in patient care quality worldwide.
Tirone E. David of the University of Toronto was presented with the 2016 AATS Scientific Achievement Award during the Annual Meeting Plenary Session on May 16th.
Dr. David (above left) with his award is shown with Dr. Irving Kron.
The award is the Association’s highest scientific recognition. Created in 1994, it recognizes physicians who have made extraordinary scientific contributions to the CT surgery field.
The honor acknowledges David’s pioneering work in CT surgery and his service as 85th AATS President (2004-2005). During an illustrious career, his innovation, passion and dedication to CT surgery has impacted hundreds of trainees and peers. The David operation revolutionized the treatment of aortic valve disease and resulted in substantial advances in patient care quality worldwide.
Meet the Newest Active AATS Members
At the Annual Meeting, 55 surgeons were elected as active AATS members:
George M. Alfieris (Rochester, NY)
Denis Bouchard (Montréal, Canada)
Ross M. Bremner (Phoenix, AZ)
Christian P. Brizard (Parkville, Australia)
Manuel Castella (Barcelona, Spain)
Renzo Cecere (Montréal, Canada)
Paul J. Chai (New York, NY)
Toyofumi F. Chen-Yoshikawa (Kyoto, Japan)
Francisco D.A. Costa (Curitiba, Brazil)
Philippe Demers (Montréal, Canada)
Benoit de Varennes (Montréal, Canada)
Roberto Di Bartolomeo (Bologna, Italy)
Nianguo Dong (Wuhan, China)
John R. Doty (Murray, UT)
Sitaram M. Emani (Boston, MA)
Jose I. Fragata (Lisbon, Portugal)
James J. Gangemi (Charlottesville, VA)
Isaac George (New York, NY)
Sebastien Gilbert (Ottawa, Canada)
Diego Gonzalez Rivas (Coruña, Spain)
Jie He (Beijing, China)
Tain-Yen Hsia (London, United Kingdom)
Aditya K. Kaza (Boston, MA)
Michael S. Kent (Boston, MA)
Zain I. Khalpey (Tucson, AZ)
Ahmet Kilic (Columbus, OH)
Joo Hyun Kim (Seoul, Republic of Korea)
Takushi Kohmoto (Madison,WI)
Buu-Khanh Lam (Ottawa, Canada)
Joseph Lamelas (Miami Beach, FL)
Hui Li (Beijing, China)
Brian E. Louie (Seattle, WA)
Giovanni Battista Luciani (Verona, Italy)
Shari L. Meyerson (Chicago, IL)
Siamak Mohammadi (Québec City, Canada)
Katie S. Nason (Pittsburgh, PA)
Shigeyuki Ozaki (Tokyo, Japan)
Amit N. Patel (Salt Lake City, UT)
Michel Pellerin (Montréal, Canada)
Mark D. Peterson (Toronto, Canada)
Eyal E. Porat (Houston, TX)
Michael F. Reed (Hershey, PA)
Kisaburo Sakamoto (Shizuoka, Japan)
Arash Salemi (New York, NY)
Norihiko Shiiya (Hamamatsu, Japan)
Hiroo Takayama (New York, NY)
Sachin Talwar (New Delhi, India)
Tomasz Timek (Grand Rapids, MI)
Joseph W. Turek (Iowa City, IA)
Pierre Voisine (Quebec, Canada)
Benny Weksler (Memphis, TN)
Grayson H. Wheatley (Philadelphia, PA)
Ronald K. Woods (Milwaukee, WI)
Hitoshi Yaku (Kyoto, Japan)
Tae-Jin Yun (Seoul, Republic of Korea)
At the Annual Meeting, 55 surgeons were elected as active AATS members:
George M. Alfieris (Rochester, NY)
Denis Bouchard (Montréal, Canada)
Ross M. Bremner (Phoenix, AZ)
Christian P. Brizard (Parkville, Australia)
Manuel Castella (Barcelona, Spain)
Renzo Cecere (Montréal, Canada)
Paul J. Chai (New York, NY)
Toyofumi F. Chen-Yoshikawa (Kyoto, Japan)
Francisco D.A. Costa (Curitiba, Brazil)
Philippe Demers (Montréal, Canada)
Benoit de Varennes (Montréal, Canada)
Roberto Di Bartolomeo (Bologna, Italy)
Nianguo Dong (Wuhan, China)
John R. Doty (Murray, UT)
Sitaram M. Emani (Boston, MA)
Jose I. Fragata (Lisbon, Portugal)
James J. Gangemi (Charlottesville, VA)
Isaac George (New York, NY)
Sebastien Gilbert (Ottawa, Canada)
Diego Gonzalez Rivas (Coruña, Spain)
Jie He (Beijing, China)
Tain-Yen Hsia (London, United Kingdom)
Aditya K. Kaza (Boston, MA)
Michael S. Kent (Boston, MA)
Zain I. Khalpey (Tucson, AZ)
Ahmet Kilic (Columbus, OH)
Joo Hyun Kim (Seoul, Republic of Korea)
Takushi Kohmoto (Madison,WI)
Buu-Khanh Lam (Ottawa, Canada)
Joseph Lamelas (Miami Beach, FL)
Hui Li (Beijing, China)
Brian E. Louie (Seattle, WA)
Giovanni Battista Luciani (Verona, Italy)
Shari L. Meyerson (Chicago, IL)
Siamak Mohammadi (Québec City, Canada)
Katie S. Nason (Pittsburgh, PA)
Shigeyuki Ozaki (Tokyo, Japan)
Amit N. Patel (Salt Lake City, UT)
Michel Pellerin (Montréal, Canada)
Mark D. Peterson (Toronto, Canada)
Eyal E. Porat (Houston, TX)
Michael F. Reed (Hershey, PA)
Kisaburo Sakamoto (Shizuoka, Japan)
Arash Salemi (New York, NY)
Norihiko Shiiya (Hamamatsu, Japan)
Hiroo Takayama (New York, NY)
Sachin Talwar (New Delhi, India)
Tomasz Timek (Grand Rapids, MI)
Joseph W. Turek (Iowa City, IA)
Pierre Voisine (Quebec, Canada)
Benny Weksler (Memphis, TN)
Grayson H. Wheatley (Philadelphia, PA)
Ronald K. Woods (Milwaukee, WI)
Hitoshi Yaku (Kyoto, Japan)
Tae-Jin Yun (Seoul, Republic of Korea)
At the Annual Meeting, 55 surgeons were elected as active AATS members:
George M. Alfieris (Rochester, NY)
Denis Bouchard (Montréal, Canada)
Ross M. Bremner (Phoenix, AZ)
Christian P. Brizard (Parkville, Australia)
Manuel Castella (Barcelona, Spain)
Renzo Cecere (Montréal, Canada)
Paul J. Chai (New York, NY)
Toyofumi F. Chen-Yoshikawa (Kyoto, Japan)
Francisco D.A. Costa (Curitiba, Brazil)
Philippe Demers (Montréal, Canada)
Benoit de Varennes (Montréal, Canada)
Roberto Di Bartolomeo (Bologna, Italy)
Nianguo Dong (Wuhan, China)
John R. Doty (Murray, UT)
Sitaram M. Emani (Boston, MA)
Jose I. Fragata (Lisbon, Portugal)
James J. Gangemi (Charlottesville, VA)
Isaac George (New York, NY)
Sebastien Gilbert (Ottawa, Canada)
Diego Gonzalez Rivas (Coruña, Spain)
Jie He (Beijing, China)
Tain-Yen Hsia (London, United Kingdom)
Aditya K. Kaza (Boston, MA)
Michael S. Kent (Boston, MA)
Zain I. Khalpey (Tucson, AZ)
Ahmet Kilic (Columbus, OH)
Joo Hyun Kim (Seoul, Republic of Korea)
Takushi Kohmoto (Madison,WI)
Buu-Khanh Lam (Ottawa, Canada)
Joseph Lamelas (Miami Beach, FL)
Hui Li (Beijing, China)
Brian E. Louie (Seattle, WA)
Giovanni Battista Luciani (Verona, Italy)
Shari L. Meyerson (Chicago, IL)
Siamak Mohammadi (Québec City, Canada)
Katie S. Nason (Pittsburgh, PA)
Shigeyuki Ozaki (Tokyo, Japan)
Amit N. Patel (Salt Lake City, UT)
Michel Pellerin (Montréal, Canada)
Mark D. Peterson (Toronto, Canada)
Eyal E. Porat (Houston, TX)
Michael F. Reed (Hershey, PA)
Kisaburo Sakamoto (Shizuoka, Japan)
Arash Salemi (New York, NY)
Norihiko Shiiya (Hamamatsu, Japan)
Hiroo Takayama (New York, NY)
Sachin Talwar (New Delhi, India)
Tomasz Timek (Grand Rapids, MI)
Joseph W. Turek (Iowa City, IA)
Pierre Voisine (Quebec, Canada)
Benny Weksler (Memphis, TN)
Grayson H. Wheatley (Philadelphia, PA)
Ronald K. Woods (Milwaukee, WI)
Hitoshi Yaku (Kyoto, Japan)
Tae-Jin Yun (Seoul, Republic of Korea)
Mechanism proposed for microvascular thrombosis in thrombotic thrombocytopenic purpura
In patients with acquired autoimmune thrombotic thrombocytopenic purpura, elevated plasma levels of human neutrophil proteins 1-3 inhibit proteolytic cleavage of von Willebrand factor by ADAMTS13, Vikram G. Pillai, PhD, of the University of Alabama at Birmingham, and colleagues reported.
The finding may explain how inflammation triggers microvascular thrombosis in these patients and potentially others with immune thrombotic disorders, according to the researchers (Blood 2016;128:110-9).
They performed enzyme-linked immunosorbent assays and found markedly increased levels of plasma human neutrophil proteins (HNPs) 1-3 in most of the patients with acquired autoimmune thrombotic thrombocytopenic purpura (TTP). The median levels in the 19 patients were 170 ng/mL, compared with 23 ng/mL in 18 healthy controls, a statistically significant difference (P less than .0001).
Liquid chromatography plus tandem mass spectrometry similarly confirmed statistically significant increases in HNP1, HNP2, and HNP3 in patient samples (P less than .001).
Measures of HNPs 1-3 by both methods correlated well, and the researchers concluded that HNPs 1-3 likely inhibit ADAMTS13 activity by binding to the central A2 domain of von Willebrand factor and physically blocking ADAMTS13 binding.
The researchers had no relevant financial disclosures.
On Twitter @maryjodales
In patients with acquired autoimmune thrombotic thrombocytopenic purpura, elevated plasma levels of human neutrophil proteins 1-3 inhibit proteolytic cleavage of von Willebrand factor by ADAMTS13, Vikram G. Pillai, PhD, of the University of Alabama at Birmingham, and colleagues reported.
The finding may explain how inflammation triggers microvascular thrombosis in these patients and potentially others with immune thrombotic disorders, according to the researchers (Blood 2016;128:110-9).
They performed enzyme-linked immunosorbent assays and found markedly increased levels of plasma human neutrophil proteins (HNPs) 1-3 in most of the patients with acquired autoimmune thrombotic thrombocytopenic purpura (TTP). The median levels in the 19 patients were 170 ng/mL, compared with 23 ng/mL in 18 healthy controls, a statistically significant difference (P less than .0001).
Liquid chromatography plus tandem mass spectrometry similarly confirmed statistically significant increases in HNP1, HNP2, and HNP3 in patient samples (P less than .001).
Measures of HNPs 1-3 by both methods correlated well, and the researchers concluded that HNPs 1-3 likely inhibit ADAMTS13 activity by binding to the central A2 domain of von Willebrand factor and physically blocking ADAMTS13 binding.
The researchers had no relevant financial disclosures.
On Twitter @maryjodales
In patients with acquired autoimmune thrombotic thrombocytopenic purpura, elevated plasma levels of human neutrophil proteins 1-3 inhibit proteolytic cleavage of von Willebrand factor by ADAMTS13, Vikram G. Pillai, PhD, of the University of Alabama at Birmingham, and colleagues reported.
The finding may explain how inflammation triggers microvascular thrombosis in these patients and potentially others with immune thrombotic disorders, according to the researchers (Blood 2016;128:110-9).
They performed enzyme-linked immunosorbent assays and found markedly increased levels of plasma human neutrophil proteins (HNPs) 1-3 in most of the patients with acquired autoimmune thrombotic thrombocytopenic purpura (TTP). The median levels in the 19 patients were 170 ng/mL, compared with 23 ng/mL in 18 healthy controls, a statistically significant difference (P less than .0001).
Liquid chromatography plus tandem mass spectrometry similarly confirmed statistically significant increases in HNP1, HNP2, and HNP3 in patient samples (P less than .001).
Measures of HNPs 1-3 by both methods correlated well, and the researchers concluded that HNPs 1-3 likely inhibit ADAMTS13 activity by binding to the central A2 domain of von Willebrand factor and physically blocking ADAMTS13 binding.
The researchers had no relevant financial disclosures.
On Twitter @maryjodales
FROM BLOOD
Key clinical point: In patients with acquired autoimmune thrombotic thrombocytopenic purpura, elevated plasma levels of human neutrophil proteins 1-3 inhibit proteolytic cleavage of von Willebrand factor by ADAMTS13.
Major finding: The median levels of plasma human neutrophil proteins 1-3 in patients with acquired autoimmune TTP were 170 ng/mL, compared with 23 ng/mL in healthy controls, a statistically significant difference (P less than .0001).
Data source: Studies in 19 patients with TTP and 18 control subjects.
Disclosures: The researchers had no relevant financial disclosures.
